Irritable Bowel Syndrome (IBS) Treatment Market Growth Outlook Through 2024-2033

Overview and Scope
Irritable bowel syndrome (IBS) treatment refers to the various approaches and interventions aimed at treating gastrointestinal tract disorders, which are frequent disorders that affect the stomach and intestines. It is used to alleviate constipation, diarrhea, and abdominal symptoms, minimize the frequency and severity of flare-ups, and enhance overall well-being.

Sizing and Forecast
The irritable bowel syndrome (ibs) treatment market size has grown rapidly in recent years. It will grow from $2.5 billion in 2023 to $2.77 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing prevalence of ibs, growing patient awareness, stress and lifestyle factors, patient advocacy and support groups, healthcare reimbursement policies.

The irritable bowel syndrome (ibs) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.29 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to patient-centric healthcare models, microbial therapies, blockchain in healthcare, patient-reported outcomes (pros), regulatory fast-track programs, health data interoperability. Major trends in the forecast period include integration of digital health solutions, advancements in diagnostic technologies, increased research and development investments, collaborations and partnerships, emergence of non-pharmacological therapies.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Segmentation & Regional Insights
The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –

1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

Major Driver Impacting Market Growth
The rise in the prevalence of irritable bowel syndrome (IBS) is expected to propel the growth of the irritable bowel syndrome treatment market going forward. IBS is a chronic gastrointestinal disorder affecting the large intestine (colon). The rise in irritable bowel syndrome (IBS) prevalence is driven by poor lifestyles, bad eating habits, exposure to pollution, and increased stress levels. IBS treatment helps to reduce the severity and frequency of IBS symptoms, improve the quality of life, and enable individuals to manage their conditions better. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD), a US-based non-profit education and research organization, about 5–10% of the global population are having IBS in 2023 and between 25 and 45 million people in the United States are affected by IBS. Therefore, the rise in the prevalence of irritable bowel syndrome (IBS) is driving the growth of the IBS treatment market.

Key Industry Players
Major companies operating in the irritable bowel syndrome (ibs) treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc. , Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., UCB SA, SK Biopharmaceuticals Co. Ltd., Celltrion Healthcare Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Protalix Biotherapeutics, Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

The irritable bowel syndrome (ibs) treatment market report table of contents includes:

1. Executive Summary
2. Irritable Bowel Syndrome (IBS) Treatment Market Characteristics
3. Irritable Bowel Syndrome (IBS) Treatment Market Trends And Strategies
4. Irritable Bowel Syndrome (IBS) Treatment Market – Macro Economic Scenario
5. Global Irritable Bowel Syndrome (IBS) Treatment Market Size and Growth
.
.
.
32. Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Benchmarking
33. Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market
35. Irritable Bowel Syndrome (IBS) Treatment Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model